The upgraded CodeFusion Studio 2.0 simplifies how developers design, test and deploy AI on embedded systems.
Updated
January 8, 2026 6:34 PM
Illustration of CodeFusion Studio™ 2.0 showing AI, code and chip icons. PHOTO: ANALOG DEVICES, INC.
Analog Devices (ADI), a global semiconductor company, launched CodeFusion Studio™ 2.0 on November 3, 2025. The new version of its open-source development platform is designed to make it easier and faster for developers to build AI-powered embedded systems that run on ADI’s processors and microcontrollers.
“The next era of embedded intelligence requires removing friction from AI development”, said Rob Oshana, Senior Vice President of the Software and Digital Platforms group at ADI. “CodeFusion Studio 2.0 transforms the developer experience by unifying fragmented AI workflows into a seamless process, empowering developers to leverage the full potential of ADI's cutting-edge products with ease so they can focus on innovating and accelerating time to market”.
The upgraded platform introduces new tools for hardware abstraction, AI integration and automation. These help developers move more easily from early design to deployment.
CodeFusion Studio 2.0 enables complete AI workflows, allowing teams to use their own models and deploy them on everything from low-power edge devices to advanced digital signal processors (DSPs).
Built on Microsoft Visual Studio Code, the new CodeFusion Studio offers built-in checks for model compatibility, along with performance testing and optimization tools that help reduce development time. Building on these capabilities, a new modular framework based on Zephyr OS lets developers test and monitor how AI and machine learning models perform in real time. This gives clearer insight into how each part of a model behaves during operation and helps fine-tune performance across different hardware setups.
Additionally, the CodeFusion Studio System Planner has also been redesigned to handle more device types and complex, multi-core applications. With new built-in diagnostic and debugging features — like integrated memory analysis and visual error tracking — developers can now troubleshoot problems faster and keep their systems running more efficiently.
This launch marks a deeper pivot for ADI. Long known for high-precision analog chips and converters, the company is expanding its edge-AI and software capabilities to enable what it calls Physical Intelligence — systems that can perceive, reason, and act locally.
“Companies that deliver physically aware AI solutions are poised to transform industries and create new, industry-leading opportunities. That's why we're creating an ecosystem that enables developers to optimize, deploy and evaluate AI models seamlessly on ADI hardware, even without physical access to a board”, said Paul Golding, Vice President of Edge AI and Robotics at ADI. “CodeFusion Studio 2.0 is just one step we're taking to deliver Physical Intelligence to our customers, ultimately enabling them to create systems that perceive, reason and act locally, all within the constraints of real-world physics”.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.